Kymera Therapeutics, Inc. (KYMR) — SEC Filings
Kymera Therapeutics, Inc. (KYMR) — 46 SEC filings. Latest: ARS (Apr 29, 2026). Includes 16 8-K, 12 SC 13G/A, 6 10-Q.
View Kymera Therapeutics, Inc. on SEC EDGAR
Overview
Kymera Therapeutics, Inc. (KYMR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 29, 2026: Kymera Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 29, 2026, for the period ending December 31, 2025. The filing, with accession number 0001193125-26-191619, details the company's operations and financial standing for the fiscal year 2025. Kymera Therapeutics, Inc.
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 43 neutral, 1 mixed. The dominant filing sentiment for Kymera Therapeutics, Inc. is neutral.
Filing Type Overview
Kymera Therapeutics, Inc. (KYMR) has filed 3 4, 1 ARS, 16 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 12 SC 13G/A, 1 SC 13G, 2 SC 13D/A, 1 SC 13D with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of KYMR's 26 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $36.34M |
| Net Income | -$224.37M |
| EPS | -$2.71 |
| Debt-to-Equity | N/A |
| Cash Position | $112.95M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Felix J. Baker
- Julian C. Baker
- Alexandra A. Toohey
- Pamela Esposito
- Dr. Nabeel K. Sarwar
- Ms. Jennifer L. Zhao
Industry Context
Kymera operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapeutics. The industry is characterized by long development cycles, high failure rates in clinical trials, and significant regulatory hurdles. Success often depends on innovation, strong intellectual property, and the ability to secure substantial funding for research, development, and eventual commercialization.
Top Tags
amendment (8) · financials (6) · institutional-ownership (6) · biotech (5) · sec-filing (4) · Biotechnology (4) · 10-Q (4) · 8-K (3) · disclosure (3) · corporate-governance (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| ARS PDF Size | 1202938 | Size of the main ARS document in bytes |
| Text File Size | 1658174 | Size of the complete submission text file in bytes |
| SEC File Number | 001-39460 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 81-2992166 | Company's tax identification number. |
| Net Loss | $224.37M | Increased from $153.11M in 2024 for the nine months ended September 30, 2025 |
| Research and Development Expenses | $232.74M | Increased from $168.43M in 2024 for the nine months ended September 30, 2025 |
| Collaboration Revenue | $36.34M | Decreased from $39.68M in 2024 for the nine months ended September 30, 2025 |
| Accumulated Deficit | $978.98M | As of September 30, 2025, indicating significant historical losses |
| Cash and Cash Equivalents | $112.95M | As of September 30, 2025, down from $120.26M at December 31, 2024 |
| Total Marketable Securities | $865.79M | As of September 30, 2025, up from $730.65M at December 31, 2024 |
| Net Proceeds from June 2025 Public Offering | $272.67M | Significant capital raised to fund operations |
| Shares of Common Stock Outstanding | 71,949,027 | As of October 31, 2025, indicating potential dilution from offerings |
| Net Loss Per Share (Q3 2025) | $0.94 | Increased from $0.82 in Q3 2024 |
| Net Loss Per Share (YTD 2025) | $2.71 | Increased from $2.09 in YTD 2024 |
| General and Administrative Expenses | $20.9M | for Q2 2025, up from $18.1M in Q2 2024 |
Forward-Looking Statements
- {"claim":"T. Rowe Price will maintain a significant stake in Kymera Therapeutics, indicating continued institutional confidence.","entity":"Kymera Therapeutics, Inc.","targetDate":"Q3 2024","confidence":"medium"}
- {"claim":"The substantial institutional ownership by T. Rowe Price could attract other institutional investors to Kymera Therapeutics.","entity":"Kymera Therapeutics, Inc.","targetDate":"Q4 2024","confidence":"low"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Kymera Therapeutics, Inc. (KYMR)?
Kymera Therapeutics, Inc. has 46 recent SEC filings from Jan 2024 to Apr 2026, including 16 8-K, 12 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KYMR filings?
Across 46 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 43 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Kymera Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kymera Therapeutics, Inc. (KYMR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kymera Therapeutics, Inc.?
Key financial highlights from Kymera Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KYMR?
The investment thesis for KYMR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kymera Therapeutics, Inc.?
Key executives identified across Kymera Therapeutics, Inc.'s filings include Felix J. Baker, Julian C. Baker, Alexandra A. Toohey, Pamela Esposito, Dr. Nabeel K. Sarwar and 1 others.
What are the main risk factors for Kymera Therapeutics, Inc. stock?
Of KYMR's 26 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Kymera Therapeutics, Inc.?
Recent forward-looking statements from Kymera Therapeutics, Inc. include guidance on {"claim":"T. Rowe Price will maintain a significant stake in Kymera Therapeutics, indicating continued institutional con and 1 other predictions.